Lyndra Therapeutics and Thermo Fisher Scientific partner to advance long-acting oral therapies

Lyndra Therapeutics and Thermo Fisher Scientific have formed a strategic collaboration to propel the development of innovative long-acting oral therapies, with a focus on enhancing patient outcomes and transforming drug delivery systems.

The partnership leverages Lyndra’s cutting-edge LYNX drug delivery platform and Thermo Fisher‘s robust capabilities in clinical research and commercial manufacturing. This collaboration is poised to advance Lyndra’s flagship therapy, oral weekly risperidone (LYN-005), as it progresses into a pivotal phase 3 safety study slated to begin in the first half of 2025.

Redefining Drug Delivery with the LYNX Platform

At the heart of this collaboration is Lyndra’s LYNX drug delivery platform, a revolutionary technology designed to provide stable and sustained medication delivery for a week or longer with a single oral dose. This innovative platform aims to improve medication adherence by reducing the frequency of dosing, a key challenge in managing chronic conditions.

Developed through more than 50 patented advancements in design, engineering, and materials science, the LYNX platform delivers medications within a targeted therapeutic window. It has demonstrated versatility across multiple therapeutic areas, offering significant potential to enhance patient care and streamline treatment regimens.

Dr. Richard Scranton, Lyndra’s President of Global Product Development, emphasized that this collaboration is a pivotal step toward scaling Lyndra’s operations and bringing its transformative therapies to broader markets. He stated that Thermo Fisher’s expertise in manufacturing and clinical research provides Lyndra with the operational infrastructure necessary to focus on advancing research and development efforts.

Thermo Fisher’s Role in Accelerating Innovation

Thermo Fisher Scientific, a global leader in serving science, is central to Lyndra’s strategy. Through its Accelerator Drug Development services, Thermo Fisher offers comprehensive 360° solutions that integrate Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO) capabilities.

This partnership enables Thermo Fisher to support Lyndra at every stage, from preclinical research to commercialization. Advanced pharmaceutical manufacturing capabilities in Cincinnati, Ohio, will serve as the foundation for Lyndra’s commercial production lines, ensuring reliable scalability for its long-acting therapies.

Michael Shafer, Executive Vice President and President of Biopharma Services at Thermo Fisher, highlighted the company’s commitment to simplifying the complex process of clinical development. He noted that this collaboration exemplifies Thermo Fisher’s dedication to accelerating the development and delivery of innovative therapies to patients worldwide.

Advancing Lyndra’s Pipeline

Lyndra’s lead investigational product, oral weekly risperidone (LYN-005), has already demonstrated its potential through the phase 3 STARLYNG-1 study, where it met its primary efficacy endpoint compared to daily Risperdal. The upcoming pivotal safety study represents the next milestone in the product’s journey toward regulatory approval and commercial availability.

By offering a weekly dosing schedule, LYN-005 aims to improve medication adherence for patients with mental health conditions, addressing a significant gap in existing treatments. This advancement aligns with Lyndra’s broader mission to revolutionize oral drug delivery and enhance the overall patient experience.

Industry Implications and Future Prospects

The partnership between Lyndra and Thermo Fisher reflects a broader trend in the biopharmaceutical industry toward long-acting therapies and patient-centric solutions. Lyndra’s LYNX platform holds significant promise for addressing unmet needs across various therapeutic areas, including mental health, infectious diseases, and chronic conditions.

Pharmaceutical companies seeking to incorporate the LYNX platform into their drug development pipelines may benefit from Thermo Fisher’s comprehensive clinical research and manufacturing capabilities. This collaboration sets a precedent for industry partnerships that prioritize innovation, scalability, and patient outcomes.

Lyndra’s Vision for Long-Acting Therapies

Lyndra’s long-acting oral therapies aim to address critical challenges in healthcare by providing solutions that improve adherence, simplify treatment regimens, and enhance clinical outcomes. The company’s strategic focus on partnerships with industry leaders like Thermo Fisher underscores its commitment to advancing patient care through innovation.

This collaboration also positions Lyndra as a key player in the evolving landscape of drug delivery technologies, with the potential to influence how pharmaceutical companies approach the development of long-acting therapies in the future.

The partnership between Lyndra Therapeutics and Thermo Fisher Scientific represents a significant advancement in the field of long-acting oral therapies. By combining Lyndra’s innovative LYNX drug delivery platform with Thermo Fisher’s world-class expertise in clinical research and manufacturing, this collaboration is poised to transform how medications are developed, delivered, and experienced by patients.